Studying senolytic drugs for secondary progressive MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether senolytic drugs (which remove aging cells) can help slow or stop worsening of secondary progressive multiple sclerosis. It may be an option if you are no longer taking MS disease-modifying therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have secondary progressive MS diagnosed with the McDonald criteria.
- Your MS has gotten worse in the past 12 months.
- You have not taken any MS disease-modifying therapy in the last 6 months, or specific strong drugs (alemtuzumab, cladribine, mitoxantrone) ever.
- You do not have serious heart, liver, kidney, or bleeding problems, and you are not taking certain medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called remibrutinib to see if it can help people with relapsing or progressive multiple sclerosis. It uses brain scans (MRI) to track how well the drug works.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This trial tests a new cell therapy (NG01) for people with secondary progressive multiple sclerosis whose disability has been worsening. It aims to see if NG01 can slow down or stop that progression.
This study tests whether two medicines (dasatinib and quercetin) can affect “cell aging” in people with chronic kidney disease related to diabetes. You may be asked to take pills for a short period and complete follow-up visits to measure how your body responds.
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Hear when a new Multiple Sclerosis (MS) Secondary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.